Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Study Purpose

This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

Participants eligible for inclusion in this study must meet all of the following criteria:
  • - Adult male and female participants aged 18 years or older at the time of screening.
  • - Weigh at least 35 kg at screening.
  • - Have a confirmed clinical diagnosis of SLE according to European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Systemic Lupus Erythematosus (SLE) classification criteria.
  • - Have a positive anti-nuclear antibody (ANA) test result; ANA titer ≥ 1:80 at screening visit based on central or local laboratory result.
  • - Active LN at screening, as defined by meeting the 3 following criteria: - Renal biopsy within 6 months prior to screening period indicating ISN/RPS class III or IV active glomerulonephritis with or without co-existing class V features, or pure class V membranous LN.
If no biopsy was performed within 6 months prior to screening period, a biopsy will need to be performed during the screening period after having met all other inclusion/exclusion criteria.
  • - UPCR ≥ 1.0 g/g on 24h urine collection at Screening.
  • - eGFR ≥ 25mL/min/1.73 m2.
Participants with eGFR < 30 mL/min/1.73 m2 require renal biopsy during the screening period showing sclerosis in ≤ 50% of glomeruli.
  • - Newly diagnosed participants as well as pre-treated LN participants (including refractory cases) can be included, as long as they are currently on, or willing to initiate SoC induction therapy for LN using MPA.
  • - Induction therapy, as defined by treatment including both high dose corticosteroids and MPA, should be initiated prior to or on day of randomization.
  • - Anti-malarial treatment at stable dosing prior to randomization is strongly recommended, in the absence of contraindications.
  • - Participants on azathioprine treatment at Screening must be switched to MPA prior to randomization.
  • - Receipt of at least one dose of pulse methylprednisolone i.v. (250 - 1000 mg per day up to 3000 mg cumulative dose) or equivalent for treatment of current episode of active LN within 60 days prior randomization.
Participant who cannot take the pulse i.v. corticosteroid therapy should directly start on 0.8-1.0 mg/day (max 80mg/day) oral predniso(lo)ne.
  • - Able to communicate well with the Investigator to understand and comply with the requirements of the study.

Exclusion Criteria:

Participants meeting any of the following criteria are not eligible for inclusion in this study:
  • - Severe renal impairment as defined by i.
) presence of oliguria (defined as a documented urine volume <400 mL/24 hrs) or ii.) End-Stage Renal Disease (ESRD) requiring dialysis or transplantation.
  • - Sclerosis in > 50% of glomeruli on renal biopsy.
  • - Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days or until the expected pharmacodynamic effect has returned to baseline.
Use of certain Traditional Chinese Medicines.
  • - Prior use of ianalumab (ever); or prior use other B cell depleting therapy within 36 weeks prior to randomization or if therapy was administered < 36 weeks prior to randomization, B cell count less than the lower limit of normal or patient's own baseline value prior to having received an earlier B cell-depleting therapy.
  • - Prior treatment with any of the following within 12 weeks prior to randomization.
  • - Belimumab, telitacicept, abatacept, TNF-α mAb, immunoglobulins (i.v./s.
c.) plasmapheresis.
  • - Any other immuno-suppressants (i.v. or oral cyclophosphamide, calcineurin inhibitors, JAK inhibitors or other kinase inhibitors) - Thalidomide treatment and/or methotrexate.
  • - Combination of DMARDs.
  • - Imidazole derivative (e.g., azathioprine, mizoribine) must be discontinued prior to starting treatment with MPA.
  • - Receipt of more than 3000 mg i.v. pulse methylprednisolone (cumulative dose) within 12 weeks prior to randomization.
  • - History of major organ transplant or hematopoietic stem cell/bone marrow transplant or are due to receive transplantation.
  • - Any one of the following laboratory values at screening: - Hemoglobin levels < 8.0 g/dL (< 5 mmol/L), or < 7.0 g/dL (< 4.3 mmol/L) if related to participant's SLE such as in active hemolytic anaemia.
  • - Platelet count < 25 x 1000/µL.
  • - Absolute neutrophil count (ANC) < 0.8 x 1000/µL.
  • - Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection or history of recurrent clinically significant infection which in the opinion of the investigator will place the participant at risk for participation.
  • - History of known intolerance/hypersensitivity to MPA, oral corticosteroids, or any component of the study drug(s) or its excipients.
  • - Receipt of live/attenuated vaccine within a 4-week period prior to randomization.
  • - History of primary or secondary immunodeficiency, including a positive HIV test result.
  • - History of malignancy of any organ system (other than localized basal cell carcinoma or squamous cell carcinoma of the skin or or in-situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
  • - Any surgical, medical (e.g., uncontrolled hypertension, heart failure or diabetes), psychiatric or additional physical condition that the Investigator feels may jeopardize the participants in case of participation in this study.
  • - Chronic infection with hepatitis B (HBV) or hepatitis C (HCV).
Positive serology for hepatitis B surface antigen (HBsAg) excludes the participant.
  • - Evidence of active tuberculosis (TB) infection (after anti-TB treatment, participants with history of TB may become eligible according to national local guidelines) - Pregnant or nursing (lactating) women.
  • - Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 6 months after stopping of investigational medication.
  • - Sexually active male participants, who do not agree to use barrier protection during intercourse with women of child-bearing potential while taking study treatment.
Other protocol -defined Inclusion/Exclusion may apply.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05126277
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Novartis Pharmaceuticals
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Novartis Pharmaceuticals
Principal Investigator Affiliation Novartis Pharmaceuticals
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Argentina, Brazil, Canada, Chile, China, Colombia, Czechia, Estonia, France, Germany, Guatemala, Hong Kong, Hungary, India, Italy, Korea, Republic of, Lithuania, Malaysia, Mexico, Romania, Singapore, Spain, Taiwan, Thailand, United Kingdom, United States, Vietnam
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Lupus Nephritis
Additional Details

This trial will evaluate the efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or ianalumab given every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN (ISN/RPS class III, IV active glomerulonephritis with or without co-existing class V features, or pure class V membranous). using the 2003 International Society for Nephrology (ISN)/Renal Pathology Society (RPS) criteria).

Arms & Interventions

Arms

Experimental: Arm 1 - ianalumab s.c. q4w

ianalumab s.c. q4w in addition to standard of care (SoC)

Experimental: Arm 2 - ianalumab s.c. q12w

ianalumab s.c. q12w in addition to SoC

Placebo Comparator: Arm 3 - placebo s.c. q4w

Placebo s.c. q4w in addition to SoC

Interventions

Drug: - ianalumab s.c. q4w

ianalumab s.c. q4w in addition to SoC

Drug: - ianalumab s.c. q12w

ianalumab s.c. q12w in addition to SoC

Drug: - placebo s.c.

placebo s.c. q4w in addition to SoC

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

University Of Alabama, Birmingham, Alabama

Status

Recruiting

Address

University Of Alabama

Birmingham, Alabama, 35294

Site Contact

Jane Vines

jsnowden@uabmc.edu

1-888-669-6682

Wallace Rheumatic Study Center, Los Angeles, California

Status

Withdrawn

Address

Wallace Rheumatic Study Center

Los Angeles, California, 90048

University of California LA, Los Angeles, California

Status

Recruiting

Address

University of California LA

Los Angeles, California, 90095

Site Contact

Lori Sahakian

LSahakian@mednet.ucla.edu

310-825-9447

University of California Irvine, Orange, California

Status

Recruiting

Address

University of California Irvine

Orange, California, 92868

Site Contact

Kelly Acero

kacero@hs.uci.edu

1-888-669-6682

UC Davis School of Medicine, Sacramento, California

Status

Recruiting

Address

UC Davis School of Medicine

Sacramento, California, 95817

Site Contact

Morgan Balaban

mbalaban@ucdavis.edu

1-888-669-6682

University of California San Diego, San Diego, California

Status

Recruiting

Address

University of California San Diego

San Diego, California, 92037

Site Contact

Linda Mendoza

lnmendoza@health.ucsd.edu

+1 858 534 2555

Kaiser Permanente, San Diego, California

Status

Recruiting

Address

Kaiser Permanente

San Diego, California, 92111

Site Contact

Jaqueline Gomez Solis

Jaqueline.X.GomezSolis@kp.org

858-401-7205

Mayo Clinic Jacksonville, Jacksonville, Florida

Status

Recruiting

Address

Mayo Clinic Jacksonville

Jacksonville, Florida, 32224

Site Contact

Carolyne Stevens

Thomas.Carolyne@mayo.edu

904-953-2451

University Of Miami, Miami, Florida

Status

Recruiting

Address

University Of Miami

Miami, Florida, 33136

Site Contact

Priscilla Madero

pdm73@med.miami.edu

305-243-2568

Emory University School of Medicine, Atlanta, Georgia

Status

Recruiting

Address

Emory University School of Medicine

Atlanta, Georgia, 30303

Site Contact

Hilton Mozee

hmozee@emory.edu

404-616-4440

Fides Clinical Research, Atlanta, Georgia

Status

Recruiting

Address

Fides Clinical Research

Atlanta, Georgia, 30342

Parris and Associates Rheumatology, Lawrenceville, Georgia

Status

Recruiting

Address

Parris and Associates Rheumatology

Lawrenceville, Georgia, 30044

University of Kansas Hospital, Kansas City, Kansas

Status

Recruiting

Address

University of Kansas Hospital

Kansas City, Kansas, 66160

UMC New Orleans, New Orleans, Louisiana

Status

Recruiting

Address

UMC New Orleans

New Orleans, Louisiana, 70112

Site Contact

Madeline Young

madeline.young@lcmchealth.org

1-888-669-6682

Wayne State University, Detroit, Michigan

Status

Recruiting

Address

Wayne State University

Detroit, Michigan, 48201

Site Contact

Yanni Zhuang

yzhuang@med.wayne.edu

313-745-7371

Univ of Nevada School of Med, Las Vegas, Nevada

Status

Recruiting

Address

Univ of Nevada School of Med

Las Vegas, Nevada, 89102

Site Contact

Katherin Mendez

katherin.mendez@unlv.edu

1-888-669-6682

Sahni Rheumatology and Therapy, West Long Branch, New Jersey

Status

Recruiting

Address

Sahni Rheumatology and Therapy

West Long Branch, New Jersey, 07764

Site Contact

Michael J Harris

m.harris@sahnirheumatology.com

732-272-1456

VA NM Healthcare System, Albuquerque, New Mexico

Status

Recruiting

Address

VA NM Healthcare System

Albuquerque, New Mexico, 87108

Site Contact

Anthony Sedillo

anthony.sedillo@va.gov

505-265-1711

James J Peters VA Medical Center, Bronx, New York

Status

Recruiting

Address

James J Peters VA Medical Center

Bronx, New York, 10468

Site Contact

Olga A Andriunas

olga.andriunas@va.gov

+17185849000#6667

NY Nephrology, Clifton Park, New York

Status

Recruiting

Address

NY Nephrology

Clifton Park, New York, 12065

Site Contact

Howard Phelan

howard.phelan@nyneph.com

518-579-0017

Hospital for Special Surgery, New York, New York

Status

Recruiting

Address

Hospital for Special Surgery

New York, New York, 10021

Site Contact

Haley Slosberg

slosbergh@hss.edu

212-606-1728

Northwell Health, New York, New York

Status

Recruiting

Address

Northwell Health

New York, New York, 10028

Site Contact

Justina D Costa

jdcosta@northwell.edu

516-708-2550

Circuit Clinical, Orchard Park, New York

Status

Recruiting

Address

Circuit Clinical

Orchard Park, New York, 14127

Brookview Hills Research Assoc, Winston-Salem, North Carolina

Status

Withdrawn

Address

Brookview Hills Research Assoc

Winston-Salem, North Carolina, 27103

University Of Cincinnati, Cincinnati, Ohio

Status

Recruiting

Address

University Of Cincinnati

Cincinnati, Ohio, 45267

Site Contact

Leksi Travitz

Leksi.travitz@uc.edu

513-559-3362

Univ of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Status

Recruiting

Address

Univ of Pennsylvania Medical Center

Philadelphia, Pennsylvania, 19104

Site Contact

Radhakrishna Kallem

Krishna.Kallem@pennmedicine.upenn.edu

1-888-669-6682

Arthritis and Rheumatology Ins, Allen, Texas

Status

Recruiting

Address

Arthritis and Rheumatology Ins

Allen, Texas, 75013

Site Contact

Kiran Khandelwal

k.khandelwal@dfwarthritis.com

1-888-669-6682

Precision Comprehensive Research, Colleyville, Texas

Status

Recruiting

Address

Precision Comprehensive Research

Colleyville, Texas, 76034

Site Contact

Ashwin Boda

ashwinboda@pccrsolutions.com

972-299-8399

Liberty Research Center, Dallas, Texas

Status

Recruiting

Address

Liberty Research Center

Dallas, Texas, 75230

Site Contact

Laurie Jones

laurie.jones@usoncology.com

972-274-5555

Univof Texas Southwestern Med Cntr, Dallas, Texas

Status

Recruiting

Address

Univof Texas Southwestern Med Cntr

Dallas, Texas, 75235

University of Texas Medical Branch, Galveston, Texas

Status

Recruiting

Address

University of Texas Medical Branch

Galveston, Texas, 77555-0144

Site Contact

Stephanie Simmons

sttsimmo@utmb.edu

409-772-1062

Uni of Texas Health Science Center, San Antonio, Texas

Status

Recruiting

Address

Uni of Texas Health Science Center

San Antonio, Texas, 78284

Baylor Scott and White Research, Temple, Texas

Status

Recruiting

Address

Baylor Scott and White Research

Temple, Texas, 76502

Site Contact

Michell Trevino

michelle.trevino1@bswhealth.org

254-935-5838

Northern Assoc of Northern VA, Fairfax, Virginia

Status

Recruiting

Address

Northern Assoc of Northern VA

Fairfax, Virginia, 22033

Uni Wisconsin School Med Pub Health, Madison, Wisconsin

Status

Recruiting

Address

Uni Wisconsin School Med Pub Health

Madison, Wisconsin, 53792

International Sites

Novartis Investigative Site, Caba, Buenos Aires, Argentina

Status

Recruiting

Address

Novartis Investigative Site

Caba, Buenos Aires, C1056ABJ

Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires, Argentina

Status

Recruiting

Address

Novartis Investigative Site

Ciudad Autonoma de Bs As, Buenos Aires, C1015ABO

Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires, Argentina

Status

Withdrawn

Address

Novartis Investigative Site

Ciudad Autonoma de Bs As, Buenos Aires, C1119ACN

Novartis Investigative Site, La Plata, Buenos Aires, Argentina

Status

Recruiting

Address

Novartis Investigative Site

La Plata, Buenos Aires, B1900AWT

Novartis Investigative Site, Ciudad Autonoma de Buenos Aire, Argentina

Status

Recruiting

Address

Novartis Investigative Site

Ciudad Autonoma de Buenos Aire, , 1426

Novartis Investigative Site, Tucuman, Argentina

Status

Recruiting

Address

Novartis Investigative Site

Tucuman, , 4000

Novartis Investigative Site, Salvador, BA, Brazil

Status

Recruiting

Address

Novartis Investigative Site

Salvador, BA, 40150 150

Novartis Investigative Site, Vitoria, ES, Brazil

Status

Recruiting

Address

Novartis Investigative Site

Vitoria, ES, 29055 450

Novartis Investigative Site, Sao Luis, Maranhao, Brazil

Status

Withdrawn

Address

Novartis Investigative Site

Sao Luis, Maranhao, 65020-600

Novartis Investigative Site, Belo Horizonte, MG, Brazil

Status

Recruiting

Address

Novartis Investigative Site

Belo Horizonte, MG, 30150-221

Novartis Investigative Site, Juiz de Fora, MG, Brazil

Status

Recruiting

Address

Novartis Investigative Site

Juiz de Fora, MG, 36010 570

Novartis Investigative Site, Curitiba, PR, Brazil

Status

Withdrawn

Address

Novartis Investigative Site

Curitiba, PR, 80440-020

Novartis Investigative Site, Pernambuco, Recife, Brazil

Status

Recruiting

Address

Novartis Investigative Site

Pernambuco, Recife, 50740-900

Novartis Investigative Site, Porto Alegre, RS, Brazil

Status

Recruiting

Address

Novartis Investigative Site

Porto Alegre, RS, 90020-090

Novartis Investigative Site, Porto Alegre, RS, Brazil

Status

Recruiting

Address

Novartis Investigative Site

Porto Alegre, RS, 90035-003

Novartis Investigative Site, Santo Andre, SP, Brazil

Status

Recruiting

Address

Novartis Investigative Site

Santo Andre, SP, 09090-790

Novartis Investigative Site, Salvador, Brazil

Status

Active, not recruiting

Address

Novartis Investigative Site

Salvador, , 40301-155

Novartis Investigative Site, Calgary, Alberta, Canada

Status

Recruiting

Address

Novartis Investigative Site

Calgary, Alberta, T2N 4Z6

Novartis Investigative Site, Vancouver, British Columbia, Canada

Status

Recruiting

Address

Novartis Investigative Site

Vancouver, British Columbia, V5Z 1L7

Novartis Investigative Site, Winnipeg, Manitoba, Canada

Status

Recruiting

Address

Novartis Investigative Site

Winnipeg, Manitoba, R3A 1R9

Novartis Investigative Site, Etobicoke, Ontario, Canada

Status

Recruiting

Address

Novartis Investigative Site

Etobicoke, Ontario, M9W 6V1

Novartis Investigative Site, London, Ontario, Canada

Status

Recruiting

Address

Novartis Investigative Site

London, Ontario, N6A 5W9

Novartis Investigative Site, Toronto, Ontario, Canada

Status

Recruiting

Address

Novartis Investigative Site

Toronto, Ontario, M5T 2S8

Novartis Investigative Site, Montreal, Quebec, Canada

Status

Recruiting

Address

Novartis Investigative Site

Montreal, Quebec, H1T 2M4

Novartis Investigative Site, Sherbrooke, Quebec, Canada

Status

Recruiting

Address

Novartis Investigative Site

Sherbrooke, Quebec, J1G 2E8

Novartis Investigative Site, Santiago, RM, Chile

Status

Recruiting

Address

Novartis Investigative Site

Santiago, RM, 7500922

Novartis Investigative Site, Temuco, Chile

Status

Recruiting

Address

Novartis Investigative Site

Temuco, , 4790084

Novartis Investigative Site, Hefei, Anhui, China

Status

Recruiting

Address

Novartis Investigative Site

Hefei, Anhui, 230022

Novartis Investigative Site, Guang Zhou, Guangdong, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Guang Zhou, Guangdong, 510120

Novartis Investigative Site, Guangzhou, Guangdong, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Guangzhou, Guangdong, 510000

Novartis Investigative Site, Guangzhou, Guangdong, China

Status

Completed

Address

Novartis Investigative Site

Guangzhou, Guangdong, 510080

Novartis Investigative Site, Shantou, Guangdong, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Shantou, Guangdong, 515041

Novartis Investigative Site, Shenzhen, Guangdong, China

Status

Withdrawn

Address

Novartis Investigative Site

Shenzhen, Guangdong, 518020

Novartis Investigative Site, Shenzhen, Guangdong, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Shenzhen, Guangdong, 518037

Novartis Investigative Site, Liuzhou, Guangxi, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Liuzhou, Guangxi, 545005

Novartis Investigative Site, Haikou, Hainan, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Haikou, Hainan, 570311

Novartis Investigative Site, Wuhan, Hubei, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Wuhan, Hubei, 430060

Novartis Investigative Site, Changsha, Hunan, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Changsha, Hunan, 410008

Novartis Investigative Site, Nanjing, Jiangsu, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Nanjing, Jiangsu, 210029

Novartis Investigative Site, Nanchang, Jiangxi, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Nanchang, Jiangxi, 330006

Novartis Investigative Site, Changchun, Jilin, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Changchun, Jilin, 130041

Novartis Investigative Site, Shenyang, Liaoning, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Shenyang, Liaoning, 110003

Novartis Investigative Site, Binzhou, Shandong, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Binzhou, Shandong, 256603

Novartis Investigative Site, Linyi, Shandong, China

Status

Recruiting

Address

Novartis Investigative Site

Linyi, Shandong, 276000

Novartis Investigative Site, Xian, Shanxi, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Xian, Shanxi, 710004

Novartis Investigative Site, Chengdu, Sichuan, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Chengdu, Sichuan, 610041

Novartis Investigative Site, Beijing, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Beijing, , 100034

Novartis Investigative Site, Chongqing, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Chongqing, , 400038

Novartis Investigative Site, Guang Zhou, China

Status

Completed

Address

Novartis Investigative Site

Guang Zhou, , 510080

Novartis Investigative Site, Guangzhou, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Guangzhou, , 510280

Novartis Investigative Site, Shanghai, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Shanghai, , 200040

Novartis Investigative Site, Shanghai, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Shanghai, , 200080

Novartis Investigative Site, Shanghai, China

Status

Completed

Address

Novartis Investigative Site

Shanghai, , 200127

Novartis Investigative Site, Wuhan, China

Status

Active, not recruiting

Address

Novartis Investigative Site

Wuhan, , 430022

Novartis Investigative Site, Zhejiang, China

Status

Recruiting

Address

Novartis Investigative Site

Zhejiang, , 315016

Novartis Investigative Site, Medellin, Antioquia, Colombia

Status

Recruiting

Address

Novartis Investigative Site

Medellin, Antioquia, 050001

Novartis Investigative Site, Bogota, Cundinamarca, Colombia

Status

Recruiting

Address

Novartis Investigative Site

Bogota, Cundinamarca, 110111

Novartis Investigative Site, Barranquilla, Colombia

Status

Recruiting

Address

Novartis Investigative Site

Barranquilla, , 080020

Novartis Investigative Site, Olomouc, Czechia

Status

Recruiting

Address

Novartis Investigative Site

Olomouc, , 779 00

Novartis Investigative Site, Praha 2, Czechia

Status

Recruiting

Address

Novartis Investigative Site

Praha 2, , 128 50

Novartis Investigative Site, Tallinn, Estonia

Status

Recruiting

Address

Novartis Investigative Site

Tallinn, , 10117

Novartis Investigative Site, Tallinn, Estonia

Status

Recruiting

Address

Novartis Investigative Site

Tallinn, , 10138

Novartis Investigative Site, Angers Cedex 9, France

Status

Recruiting

Address

Novartis Investigative Site

Angers Cedex 9, , 49933

Novartis Investigative Site, Besancon Cedex, France

Status

Recruiting

Address

Novartis Investigative Site

Besancon Cedex, , 25030

Novartis Investigative Site, Bordeaux Cedex, France

Status

Recruiting

Address

Novartis Investigative Site

Bordeaux Cedex, , 33076

Novartis Investigative Site, Grenoble, France

Status

Recruiting

Address

Novartis Investigative Site

Grenoble, , 38043

Novartis Investigative Site, Lyon, France

Status

Recruiting

Address

Novartis Investigative Site

Lyon, , 69003

Novartis Investigative Site, Marseille, France

Status

Recruiting

Address

Novartis Investigative Site

Marseille, , 13385

Novartis Investigative Site, Poitiers, France

Status

Recruiting

Address

Novartis Investigative Site

Poitiers, , 86021

Novartis Investigative Site, Regensburg, Bavaria, Germany

Status

Withdrawn

Address

Novartis Investigative Site

Regensburg, Bavaria, 93053

Novartis Investigative Site, Aachen, Germany

Status

Recruiting

Address

Novartis Investigative Site

Aachen, , 52074

Novartis Investigative Site, Bochum, Germany

Status

Recruiting

Address

Novartis Investigative Site

Bochum, , 44791

Novartis Investigative Site, Muenster, Germany

Status

Recruiting

Address

Novartis Investigative Site

Muenster, , 48149

Novartis Investigative Site, Guatemala City, Guatemala

Status

Recruiting

Address

Novartis Investigative Site

Guatemala City, , 01011

Novartis Investigative Site, Guatemala, Guatemala

Status

Recruiting

Address

Novartis Investigative Site

Guatemala, , 01010

Novartis Investigative Site, Quetzaltenango, Guatemala

Status

Recruiting

Address

Novartis Investigative Site

Quetzaltenango, , 9001

Novartis Investigative Site, Kwun Tong, Kowloon, Hong Kong

Status

Recruiting

Address

Novartis Investigative Site

Kwun Tong, Kowloon,

Novartis Investigative Site, Tuen Mun, Hong Kong

Status

Recruiting

Address

Novartis Investigative Site

Tuen Mun, , 999077

Novartis Investigative Site, Budapest, Hungary

Status

Recruiting

Address

Novartis Investigative Site

Budapest, , H-1032

Novartis Investigative Site, Budapest, Hungary

Status

Recruiting

Address

Novartis Investigative Site

Budapest, , H-1097

Novartis Investigative Site, Debrecen, Hungary

Status

Recruiting

Address

Novartis Investigative Site

Debrecen, , 4032

Novartis Investigative Site, Kaposvar, Hungary

Status

Recruiting

Address

Novartis Investigative Site

Kaposvar, , 7400

Novartis Investigative Site, Bangalore, Karnataka, India

Status

Recruiting

Address

Novartis Investigative Site

Bangalore, Karnataka, 560 079

Novartis Investigative Site, Secunderabad, Telangana, India

Status

Recruiting

Address

Novartis Investigative Site

Secunderabad, Telangana, 500003

Novartis Investigative Site, Lucknow, Uttar Pradesh, India

Status

Recruiting

Address

Novartis Investigative Site

Lucknow, Uttar Pradesh, 226014

Novartis Investigative Site, Chandigarh, India

Status

Recruiting

Address

Novartis Investigative Site

Chandigarh, , 160 012

Novartis Investigative Site, Cagliari, CA, Italy

Status

Recruiting

Address

Novartis Investigative Site

Cagliari, CA, 09134

Novartis Investigative Site, Foggia, FG, Italy

Status

Recruiting

Address

Novartis Investigative Site

Foggia, FG, 71122

Novartis Investigative Site, Firenze, FI, Italy

Status

Recruiting

Address

Novartis Investigative Site

Firenze, FI, 50134

Novartis Investigative Site, Milano, MI, Italy

Status

Recruiting

Address

Novartis Investigative Site

Milano, MI, 20132

Novartis Investigative Site, Pavia, PV, Italy

Status

Recruiting

Address

Novartis Investigative Site

Pavia, PV, 27100

Novartis Investigative Site, Roma, RM, Italy

Status

Recruiting

Address

Novartis Investigative Site

Roma, RM, 00168

Novartis Investigative Site, Torino, TO, Italy

Status

Recruiting

Address

Novartis Investigative Site

Torino, TO, 10154

Novartis Investigative Site, Udine, UD, Italy

Status

Recruiting

Address

Novartis Investigative Site

Udine, UD, 33100

Novartis Investigative Site, Napoli, Italy

Status

Withdrawn

Address

Novartis Investigative Site

Napoli, , 80131

Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of

Status

Recruiting

Address

Novartis Investigative Site

Bundang Gu, Gyeonggi Do, 13620

Novartis Investigative Site, Suwon si, Gyeonggi Do, Korea, Republic of

Status

Recruiting

Address

Novartis Investigative Site

Suwon si, Gyeonggi Do, 16499

Novartis Investigative Site, Daejeon, Korea, Korea, Republic of

Status

Withdrawn

Address

Novartis Investigative Site

Daejeon, Korea, 35015

Novartis Investigative Site, Busan, Korea, Republic of

Status

Recruiting

Address

Novartis Investigative Site

Busan, , 602 715

Novartis Investigative Site, Daegu, Korea, Republic of

Status

Recruiting

Address

Novartis Investigative Site

Daegu, , 705 718

Novartis Investigative Site, Gwangju, Korea, Republic of

Status

Recruiting

Address

Novartis Investigative Site

Gwangju, , 61469

Novartis Investigative Site, Seoul, Korea, Republic of

Status

Recruiting

Address

Novartis Investigative Site

Seoul, , 03722

Novartis Investigative Site, Seoul, Korea, Republic of

Status

Recruiting

Address

Novartis Investigative Site

Seoul, , 04763

Novartis Investigative Site, Seoul, Korea, Republic of

Status

Recruiting

Address

Novartis Investigative Site

Seoul, , 05030

Novartis Investigative Site, Seoul, Korea, Republic of

Status

Recruiting

Address

Novartis Investigative Site

Seoul, , 05505

Novartis Investigative Site, Seoul, Korea, Republic of

Status

Recruiting

Address

Novartis Investigative Site

Seoul, , 06591

Novartis Investigative Site, Kaunas, LTU, Lithuania

Status

Recruiting

Address

Novartis Investigative Site

Kaunas, LTU, LT 50161

Novartis Investigative Site, Vilnius, Lithuania

Status

Recruiting

Address

Novartis Investigative Site

Vilnius, , LT-08661

Novartis Investigative Site, Sibu, Sarawak, Malaysia

Status

Recruiting

Address

Novartis Investigative Site

Sibu, Sarawak, 96000

Novartis Investigative Site, Kuala Terengganu, Terengganu, Malaysia

Status

Recruiting

Address

Novartis Investigative Site

Kuala Terengganu, Terengganu, 20400

Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia

Status

Recruiting

Address

Novartis Investigative Site

Kuala Lumpur, Wilayah Persekutuan, 50586

Novartis Investigative Site, Leon, Guanajuato, Mexico

Status

Recruiting

Address

Novartis Investigative Site

Leon, Guanajuato, 37160

Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico

Status

Recruiting

Address

Novartis Investigative Site

Monterrey, Nuevo Leon, 64440

Novartis Investigative Site, Oaxaca, Mexico

Status

Recruiting

Address

Novartis Investigative Site

Oaxaca, , 68020

Novartis Investigative Site, Queretaro, Mexico

Status

Withdrawn

Address

Novartis Investigative Site

Queretaro, , 76000

Novartis Investigative Site, Queretaro, Mexico

Status

Recruiting

Address

Novartis Investigative Site

Queretaro, , 76070

Novartis Investigative Site, Oradea, Jud Bihor, Romania

Status

Recruiting

Address

Novartis Investigative Site

Oradea, Jud Bihor, 410619

Novartis Investigative Site, Ramnicu Valcea, Valcea, Romania

Status

Withdrawn

Address

Novartis Investigative Site

Ramnicu Valcea, Valcea, 240672

Novartis Investigative Site, Bucharest, Romania

Status

Recruiting

Address

Novartis Investigative Site

Bucharest, , 022328

Novartis Investigative Site, Bucuresti, Romania

Status

Recruiting

Address

Novartis Investigative Site

Bucuresti, , 011172

Novartis Investigative Site, Cluj Napoca, Romania

Status

Recruiting

Address

Novartis Investigative Site

Cluj Napoca, , 400006

Novartis Investigative Site, Timisoara, Romania

Status

Recruiting

Address

Novartis Investigative Site

Timisoara, , 300736

Novartis Investigative Site, Singapore, Singapore

Status

Recruiting

Address

Novartis Investigative Site

Singapore, , 169608

Novartis Investigative Site, Singapore, Singapore

Status

Recruiting

Address

Novartis Investigative Site

Singapore, , S308433

Novartis Investigative Site, Barcelona, Catalunya, Spain

Status

Recruiting

Address

Novartis Investigative Site

Barcelona, Catalunya, 08003

Novartis Investigative Site, Barcelona, Catalunya, Spain

Status

Recruiting

Address

Novartis Investigative Site

Barcelona, Catalunya, 08035

Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain

Status

Recruiting

Address

Novartis Investigative Site

Valencia, Comunidad Valenciana, 46017

Novartis Investigative Site, Santiago De Compostela, Galicia, Spain

Status

Recruiting

Address

Novartis Investigative Site

Santiago De Compostela, Galicia, 15706

Novartis Investigative Site, El Palmar, Murcia, Spain

Status

Withdrawn

Address

Novartis Investigative Site

El Palmar, Murcia, 30120

Novartis Investigative Site, Pamplona, Navarra, Spain

Status

Recruiting

Address

Novartis Investigative Site

Pamplona, Navarra, 31008

Novartis Investigative Site, Vigo, Pontevedra, Spain

Status

Recruiting

Address

Novartis Investigative Site

Vigo, Pontevedra, 36200

Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, Spain

Status

Recruiting

Address

Novartis Investigative Site

La Laguna, Santa Cruz De Tenerife, 38320

Novartis Investigative Site, Madrid, Spain

Status

Recruiting

Address

Novartis Investigative Site

Madrid, , 28040

Novartis Investigative Site, Madrid, Spain

Status

Recruiting

Address

Novartis Investigative Site

Madrid, , 28041

Novartis Investigative Site, Madrid, Spain

Status

Recruiting

Address

Novartis Investigative Site

Madrid, , 280796

Novartis Investigative Site, Kaohsiung, Taiwan

Status

Recruiting

Address

Novartis Investigative Site

Kaohsiung, , 83301

Novartis Investigative Site, Taichung, Taiwan

Status

Recruiting

Address

Novartis Investigative Site

Taichung, , 40447

Novartis Investigative Site, Taichung, Taiwan

Status

Recruiting

Address

Novartis Investigative Site

Taichung, , 407219

Novartis Investigative Site, Taipei, Taiwan

Status

Recruiting

Address

Novartis Investigative Site

Taipei, , 11217

Novartis Investigative Site, Songkhla, Hat Yai, Thailand

Status

Recruiting

Address

Novartis Investigative Site

Songkhla, Hat Yai, 90110

Novartis Investigative Site, Bangkok, Thailand

Status

Recruiting

Address

Novartis Investigative Site

Bangkok, , 10330

Novartis Investigative Site, Bangkok, Thailand

Status

Recruiting

Address

Novartis Investigative Site

Bangkok, , 10400

Novartis Investigative Site, Bangkok, Thailand

Status

Recruiting

Address

Novartis Investigative Site

Bangkok, , 10700

Novartis Investigative Site, Chiang Mai, Thailand

Status

Recruiting

Address

Novartis Investigative Site

Chiang Mai, , 50200

Novartis Investigative Site, Bradford, West Yorkshire, United Kingdom

Status

Recruiting

Address

Novartis Investigative Site

Bradford, West Yorkshire, BD9 6RJ

Novartis Investigative Site, London, United Kingdom

Status

Recruiting

Address

Novartis Investigative Site

London, , SE1 9RT

Novartis Investigative Site, Hanoi, Vietnam

Status

Recruiting

Address

Novartis Investigative Site

Hanoi, , 100000

Novartis Investigative Site, Ho Chi Minh, Vietnam

Status

Active, not recruiting

Address

Novartis Investigative Site

Ho Chi Minh, , 700000